$599

MIRA Acquires SKNY for CB1 Asset; Structure Initiates Ph2 Body Composition Study

Two cardiometabolic-related news items have been observed: MIRA Pharmaceuticals acquired SKNY Pharmaceuticals, including its lead CB1 inhibitor for obesity and addiction (view press release); and Structure Therapeutics initiated its Ph2 study evaluating aleniglipron on body composition in participants with obesity (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here